Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC.
Jebbink M, de Langen AJ, Monkhorst K, Boelens MC, van den Broek D, van der Noort V, de Gooijer CJ, Mahn M, van der Wekken AJ, Hendriks L, Hashemi SMS, Paats MS, Dingemans AC, Smit EF. Jebbink M, et al. Among authors: de langen aj, de gooijer cj. JTO Clin Res Rep. 2023 Feb 24;4(4):100481. doi: 10.1016/j.jtocrr.2023.100481. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37035409 Free PMC article.
Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.
Bubendorf L, Lantuejoul S, de Langen AJ, Thunnissen E. Bubendorf L, et al. Among authors: de langen aj. Eur Respir Rev. 2017 Jun 28;26(144):170007. doi: 10.1183/16000617.0007-2017. Print 2017 Jun 30. Eur Respir Rev. 2017. PMID: 28659503 Free PMC article. Review.
Sotorasib in KRASG12C mutated lung cancer - Authors' reply.
Paz-Ares L, Mehta B, Wang Y, Obiozor C, Waterhouse D, de Langen AJ. Paz-Ares L, et al. Among authors: de langen aj. Lancet. 2024 Jan 13;403(10422):145-146. doi: 10.1016/S0140-6736(23)02036-6. Lancet. 2024. PMID: 38218612 No abstract available.
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.
Dingemans AC, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, Scholtens HTGM, van Tinteren H, Hoekstra OS, Pruim J, Brans B, Thunnissen FB, Smit EF, Groen HJM. Dingemans AC, et al. Among authors: de langen aj. Ann Oncol. 2011 Mar;22(3):559-566. doi: 10.1093/annonc/mdq391. Epub 2010 Aug 11. Ann Oncol. 2011. PMID: 20702788 Free article. Clinical Trial.
Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI.
de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, Pruim J, Brans B, Leffers P, Dingemans AM, Smit EF, Groen HJ, Hoekstra OS. de Langen AJ, et al. J Nucl Med. 2011 Jan;52(1):48-55. doi: 10.2967/jnumed.110.078261. Epub 2010 Dec 13. J Nucl Med. 2011. PMID: 21149474 Free article. Clinical Trial.
Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis.
de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, Boers M, Smit EF, Stroobants S, Weber WA, Hoekstra OS. de Langen AJ, et al. J Nucl Med. 2012 May;53(5):701-8. doi: 10.2967/jnumed.111.095299. Epub 2012 Apr 10. J Nucl Med. 2012. PMID: 22496583 Free article.
102 results